Vor(US:VOR)2021-11-19 19:00Vor Biopharma's Platform and Vision - Vor Biopharma is focused on curing blood cancers through cell and genome engineering[11] - The company's paradigm involves engineering hematopoietic stem cells (eHSCs) to remove target expression on healthy cells, making cancer killing more specific[7] - Vor's platform combines genome engineering with hematopoietic stem cells and CAR-T-cell therapies to create treatment-resistant transplants[10] VOR33 and VCAR33 Programs - VOR33 aims to provide treatment-resistant HSC transplants[19] - VCAR33 is an allogeneic CAR-T therapy with potential advantages for healthy donor cell source and addressing tumor heterogeneity[24] - The VCAR33 construct is being studied in a Phase 1/2 clinical trial sponsored by the National Marrow Donor Program (NMDP)[26] Clinical Development and Milestones - Vor anticipates initial clinical data for VOR33 in the first half of 2022[25,73] - The company plans to file an IND for the VOR33 + VCAR33 treatment system in the second half of 2022, following initial VOR33 and NMDP clinical data[25,73] - A Phase 1/2a clinical trial (VBP101) is underway, evaluating VOR33 + Mylotarg in transplant-eligible AML patients at high risk of relapse[48,49] Market and Financial Position - Approximately 20,000 AML cases are diagnosed annually[13] - For patients who relapse post-transplant, 2-year survival is less than 20%[17] - Vor Biopharma secured $203 million in gross proceeds from its IPO in February 2021, providing a cash runway into mid-2023[73]